Amgen Inc. or Galapagos NV: Who Leads in Yearly Revenue?

Amgen Inc. vs. Galapagos NV: A Revenue Showdown

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Amgen Inc. has consistently outperformed Galapagos NV in terms of annual revenue. From 2014 to 2023, Amgen's revenue surged by approximately 40%, reaching a peak of $28 billion in 2023. In contrast, Galapagos NV, despite its innovative strides, saw its revenue fluctuate, peaking at around $845 million in 2019 before declining to $240 million in 2023.

This stark contrast highlights Amgen's robust market presence and strategic growth initiatives. While Galapagos NV has shown potential, its revenue remains a fraction of Amgen's, underscoring the challenges smaller biotech firms face in scaling operations. As the industry evolves, the revenue trajectories of these companies will be crucial in determining their future market positions.